Listed by the USPTO as BORGEEST, CHRISTINA M
Tech Center 1600 • Art Units: 1643 1645 1649 1674 1675
This examiner grants 56% of resolved cases
BORGEEST, CHRISTINA M is assigned to tech center 1600 and art unit 1643. The record includes 729 resolved cases and an allowance rate of 55.7%. The median time to allowance is 1160 days, indicating a prolonged prosecution path for matters that reach allowance.
Interviews are associated with a 21.4% lift in the allowance rate. That positive relationship supports considering an interview when the applicant has a focused position on claim scope or cited art. The listed companies are Boehringer Ingelheim International GmbH, Eli Lilly and Company, and THE GENERAL HOSPITAL Corporation. The listed firms are Jones Day, Silvia Salvadori, P.C., and BROWN RUDNICK LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17759056 | MYELOID-DERIVED GROWTH FACTOR FOR USE IN TREATING OR PREVENTING FIBROSIS, HYPERTROPHY OR HEART FAILURE | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18645005 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18008324 | ACVR1 (ALK2) RECEPTOR INHIBITION TO TREAT NEUROLOGICAL DISEASES | Final Rejection | The Regents of the University of California |
| 18177566 | COMPOSITIONS AND METHODS FOR CROSSING BLOOD BRAIN BARRIER | Non-Final OA | California Institute of Technology |
| 18798878 | AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZING AND MODIFYING THEREOF | Non-Final OA | Amgen Inc. |
| 18250107 | BRAIN PENETRATING PEPTIDES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18576049 | MEANS AND METHODS FOR THE TREATMENT OF CALCIUM CRYSTAL DEPOSITION DISEASES | Non-Final OA | ACADEMISCH ZIEKENHUIS MAASTRICHT |
| 18511825 | RECOMBINANT TIM-4 PROTEIN, CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL DELIVERY SYSTEM AND METHODS OF MAKING AND USING SAME | Non-Final OA | Duke University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy55.7% of resolved applications examined by Christina M Borgeest were allowed (729 resolved cases), compared with 41.5% across Art Unit 1643 over the last five years.
This examiner's interview lift is +21.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Christina M Borgeest took 1,160 days on average from filing to allowance.
Christina M Borgeest examines applications in Art Unit 1643 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
